Zhejiang Tailin BioEngineering Co.,Ltd (300813.SZ), founded in 2002 and headquartered in Hangzhou, China, provides integrated life science system solutions focused on microbial detection, contamination control, aseptic isolation, and analytical instrumentation for the biopharmaceutical, medical, biosafety, food, environmental, and electronics industries. The company manufactures and sells core products including sterility testing systems such as bacteria collectors, sterility test pumps, and single-closed sterile canisters; aseptic isolators and negative isolators for cell and gene therapy (ATMPs) and radiopharmaceuticals; VHPS vapor hydrogen peroxide decontamination and biodecontamination systems; glove integrity testers and leak detectors; total organic carbon (TOC) analyzers with dual-wave UV oxidation; filter integrity testers and membrane filtration systems; microbial limit testing systems with reusable filters; dissolution testers; shakers; and related consumables and technical services including validation, installation, and qualification support. Tailin operates subsidiaries covering microbiological analysis, medical engineering for biosafety and isolation, analytical instruments, and international business, with products serving customers in over 40 countries and holding more than 300 patents while contributing to national standards and the Chinese Pharmacopoeia. In recent developments, the company advances its globalization strategy through participation in major 2025 exhibitions including CPHI&PMEC China (June), Maghreb Pharma Expo in Algeria (April), and MIECF in Macao (March), following 2024 events at CPHI Milan, CPHI SEA in Thailand, and FILTECH in Germany that strengthened Southeast Asian and European market ties; Tailin also hosted a successful 2024 Open Day for international customers and continues industrialization of cell and gene therapy isolator workstations with nine related patents.